News Headlines Article

Bill that aimed to shed light on specialty prescription drug pricing is shelved
Los Angeles Times

In a battle between two Capitol lobbying heavyweights — health insurers and pharmaceutical companies — the latter scored a major win Tuesday, beating back a measure designed to provide more transparency on prescription drug pricing.

Assemblyman David Chiu (D-San Francisco) declined to put his transparency measure up for a vote in a key committee Tuesday, effectively killing the bill.

The measure, a holdover from last year, would have required drug companies to report costs — including spending on research and marketing — and profits associated with any drug that has a wholesale price topping $10,000 a year or per treatment course.